Skip to content
GLOBALANCE INTELLIGENCEThe economy ahead.
This Week Index 28/100 Sign in
Money & Investments › GI 100 Index
The Great Value ShiftInvestment ThemesGI 100 IndexGI PortfolioStart Future Check
AI FOOTPRINTlimitedASSESSMENT 2026GLOBALANCEINTELLIGENCE
Globalance AI Footprint

Assessment as of November 2026 · next assessment 2027.

Result of the assessment by the Globalance research team under the published methodology. Not a certification or quality label.

How we assess ›

How this rating is builtVideo · 0:52
GI 100 Index · Profile

Regeneron Pharmaceuticals

USAAdoptersAssignment FullData quality Medium

Key messagelimited AI Footprint

Regeneron has anchored oversight of artificial intelligence on its board in a dedicated committee and describes its protection of data and systems in specific terms in its mandatory reports to the securities regulator. How new AI applications are reviewed and approved and how the health and genomic data of millions of people are used for AI training, the company has so far disclosed only in general principles.

Opportunities

  • Safetysolid

    Technical data and system protection is described in specific terms in the 10-K: a CISO, a Technology Risk Management Committee, external assessors, supplier due diligence and committee oversight including the response to data protection breaches (S02, S05, S06).

    Technical data and system protection is described in specific terms in the 10-K: a CISO, a Technology Risk Management Committee, external assessors, supplier due diligence and committee oversight including the response to data protection breaches (S02, S05, S06). For AI-specific reliability (validation, red-teaming, monitoring) there are only company statements and a job posting (S12, S25). The 2024 data incident at the service provider Cencora/Lash Group affected patient data from Regeneron programmes, but is unrelated to AI and without established responsibility on Regeneron's part (S19, S20).

Risks

  • Responsibilitylimited

    Condition (a) of the minimum requirement is met: since April 2026 the board's Digital Technology Committee has explicitly overseen AI strategy, the AI governance framework and digital technology risks, and before that the Audit Committee named AI as a focus (S04, S05, S06).

    Condition (a) of the minimum requirement is met: since April 2026 the board's Digital Technology Committee has explicitly overseen AI strategy, the AI governance framework and digital technology risks, and before that the Audit Committee named AI as a focus (S04, S05, S06). Condition (b) is not met: an AI Advisory Committee, review of new AI solutions before approval, a ban on entering confidential data and supplier due diligence are described only in a position statement of lower evidence grade (S07), and a job posting from October 2026 shows that a risk taxonomy and classification are still being built (S25); an AI policy or approval procedure with primary evidence is missing. The pillar is therefore “limited” on the basis of principles; AI metrics, AI training and external audits are not documented, and the grievance channels are general (S08).

  • Transparencylimited

    Regeneron discloses the types of AI used and its principles and commits to informing users about AI interaction where possible and to documenting decision logic (S07).

    Regeneron discloses the types of AI used and its principles and commits to informing users about AI interaction where possible and to documenting decision logic (S07). On its own models and on the use of health data of hundreds of millions of people for AI training there are only press releases without information on models, limits or consent (S13, S14). All transparency evidence consists of grade C company statements; the AI risk factors in the 10-K could not be read.

  • Risk area

    Use of sensitive genomic and health data of millions of people for AI

  • Risk area

    AI in GxP-regulated processes such as clinical development and manufacturing

  • No serious controversy recorded.

What lies behind the assessment

Research of 3 November 2026
42searches
32pages and documents read
10primary documents
1controversies checked
5open points, named openly
The full research: pillars, evidence, controversies and open points
AI Footprint · Adopter · As of 3 November 2026
Regeneron PharmaceuticalsOverall rating: limited

Regeneron has assigned oversight of AI to a dedicated board committee and describes its system protection in detail in the 10-K. How it tests its own AI and uses health data for AI training, Regeneron discloses only in principles.

Safety

40 %
limitedsolidstrong

Data and system protection is described in detail in the 10-K, but AI testing is not.

  • +Item 1C names a CISO, external assessors and supplier due diligence Source ↗
  • +Committee oversees the data breach response plan Source ↗
  • –AI validation and red-teaming still being built, per job posting Source ↗
  • –Data breach at service provider Cencora with Regeneron patient data Source ↗
All sources for this pillar (11)

Transparency

20 %
limitedsolidstrong

Types of AI and principles are disclosed, but not models and data use.

  • +Position statement names AI types used and a labelling duty Source ↗
  • +TriNetX collaboration openly communicated as a basis for AI training Source ↗
  • –No information on consent and provenance of training data Source ↗
  • –No register of AI systems in use and no model documentation
All sources for this pillar (5)
What is missing for “strong”

These steps are in the company’s own hands.

1Responsibility
Complete the AI risk framework

Publish an AI policy with risk classes and an approval process and back it with metrics and an external audit.

2Safety
Document AI validation

Describe validation, red-teaming and monitoring of AI, including in GxP processes, and have them independently audited.

3Transparency
Disclose data use for AI

Document consent, provenance and protection of the health data used for AI training, as well as its own models.

Context: 101 companies assessed

Distribution of overall ratings, no ranking
strong
none yet
solid
limited
← Regeneron Pharmaceuticals is one of 66

No company reaches “strong” today. Disclosure on how companies handle AI is still young across the market.

Controversies
1 1 minor

No deduction for controversies.

Largest risk area
AI training on health data

Via TriNetX and Truveta, Regeneron makes health data of hundreds of millions of people usable for AI training; the information is limited to de-identification and legal compliance.

How thoroughly assessed
25 Evidence

10 primary documents read, 42 searches.

Read the full reasoning and all sources
Regeneron Pharmaceuticals · Full reasoning

AI committee on the board, but only principles on AI review and health data

Overall rating “limited”. No deduction for controversies. The superscript numbers link directly to the source.

1 · Responsibility

limitedWeight 40%

Board oversight of AI is documented in SEC filings, but review and approval of AI rest only on a position statement, and according to a job posting the risk taxonomy is still being built.

What is documented
  • Since April 2026 the Digital Technology Committee has been responsible for the strategic use of AI and the governance framework and meets at least twice a year1 2 3
  • Previously the Audit Committee named AI and digital technology as a focus; one director brings AI expertise2 1
  • The position statement requires review of new AI solutions before approval, human review of outputs and supplier due diligence4
  • At management level there is an AI Advisory Committee and the position of a Chief AI Officer4 5
  • General reporting channels with a ban on retaliation exist; 99.6% completed code of conduct training in 20257 8
The case against
Controls still being built
  • A job posting from October 2026 only now plans to establish a risk taxonomy, classification standards and a lifecycle standard5
  • An AI policy with risk classes and a described approval process are not published
Missing accountability
  • No AI report, AI metrics, AI training rate or external audit was found; the 2024 and 2025 sustainability reports could not be retrieved
  • The grievance channels are general, without reference to AI and without documented remedy7
Sources for Responsibility (9)
  1. Regeneron Pharmaceuticals, Inc. (SEC EDGAR): Definitive Proxy Statement (DEF 14A) 2026, Annual Meeting 12 June 2026 · 24 April 2026 · primary source
  2. Regeneron Pharmaceuticals, Inc. (SEC EDGAR): Proxy Statement 2026, courtesy PDF · 24 April 2026 · primary source
  3. Regeneron Pharmaceuticals, Inc. (Investor Relations): Charter of the Digital Technology Committee of the Board of Directors · 3 November 2026 · primary source
  4. Regeneron Pharmaceuticals, Inc.: Position Statement on Responsible Use of Artificial Intelligence · 1 July 2025 · secondary source
  5. Regeneron Pharmaceuticals, Inc. (careers page): Executive Director, Responsible AI & Enterprise Governance (R49699) · 14 October 2026 · secondary source
  6. Regeneron Pharmaceuticals, Inc. (SEC EDGAR, XBRL): 10-K FY2025, R29: Cybersecurity Risk Management and Strategy Disclosure (Item 1C) · 4 February 2026 · primary source
  7. Regeneron Pharmaceuticals, Inc.: Code of Business Conduct and Ethics · 7 October 2026 · secondary source
  8. Regeneron Pharmaceuticals, Inc.: Achieving Our 2025 Responsibility Goals · 31 December 2025 · secondary source
  9. Regeneron Pharmaceuticals, Inc.: Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year · 16 December 2024 · secondary source

2 · Safety

solidWeight 40%

Regeneron describes in the 10-K a cybersecurity programme with a CISO, external assessors and committee oversight, but for validation and monitoring of AI there are only company statements.

What is documented
  • Item 1C describes risk assessment, monitoring and testing of systems, external assessors, supplier due diligence and reports to the Audit Committee4
  • A Technology Risk Management Committee assesses technology risks within the enterprise risk programme4
  • Since April 2026 the Digital Technology Committee has overseen the data breach response plan and the data governance framework5 6
  • The Regeneron Genetics Center prohibits re-identification attempts; the TriNetX matching uses «privacy-preserving methods»7 8
  • The position statement requires protection against data leakage when using AI with confidential information1
The case against
Missing evidence of AI testing
  • A validation framework, red-teaming, production monitoring and GxP validation of AI are tasks of a position advertised in October 20263
  • On ongoing model validation there is only a statement by the Genetics Center2
  • An independent audit of the genomic and AI data environments is not documented
Data incident at a service provider
  • In 2024 names, diagnoses and medications of patients of several drug companies, including Regeneron, were stolen at Cencora/Lash Group10 11
Sources for Safety (11)
  1. Regeneron Pharmaceuticals, Inc.: Position Statement on Responsible Use of Artificial Intelligence · 1 July 2025 · secondary source
  2. Regeneron Pharmaceuticals, Inc.: From Human Data to Human Health (Regeneron Genetics Center) · 3 November 2026 · secondary source
  3. Regeneron Pharmaceuticals, Inc. (careers page): Executive Director, Responsible AI & Enterprise Governance (R49699) · 14 October 2026 · secondary source
  4. Regeneron Pharmaceuticals, Inc. (SEC EDGAR, XBRL): 10-K FY2025, R29: Cybersecurity Risk Management and Strategy Disclosure (Item 1C) · 4 February 2026 · primary source
  5. Regeneron Pharmaceuticals, Inc. (SEC EDGAR): Proxy Statement 2026, courtesy PDF · 24 April 2026 · primary source
  6. Regeneron Pharmaceuticals, Inc. (Investor Relations): Charter of the Digital Technology Committee of the Board of Directors · 3 November 2026 · primary source
  7. Regeneron Pharmaceuticals, Inc.: Regeneron Genetics Center Data Privacy Statement · 1 May 2025 · secondary source
  8. Regeneron Pharmaceuticals, Inc. (GlobeNewswire): Regeneron Collaborates with TriNetX to Access De-identified Electronic Health Records of 300 Million Patients · 2 April 2026 · secondary source
  9. Board Cybersecurity: Regeneron Pharmaceuticals, Inc. Cybersecurity Incident (Tracker) · 22 May 2024 · secondary source
  10. Claim Depot: Regeneron Pharmaceuticals, Inc. Data Breach · 24 May 2024 · secondary source
  11. BleepingComputer: Cencora data breach exposes US patient info from 11 drug companies · 24 May 2024 · secondary source

3 · Transparency

limitedWeight 20%

Regeneron names the types of AI used and its principles, but discloses neither limits nor consent information on its own models and the use of health data for AI training.

What is documented
  • The position statement names machine learning, language processing, large language models and process automation as types of AI used1
  • Regeneron commits to labelling AI interaction «where possible», disclosing AI-generated content in publications and documenting decisions of AI solutions1
  • The position statement prohibits letting AI replace critical decisions such as hiring1
  • Regeneron names its data holdings: over 3 million exomes, data on around 300 million people via TriNetX and 10 million exomes at Truveta4 2 5
The case against
Principles only
  • On the use of TriNetX and Truveta data for AI training there are only press releases without information on models, limits or consent2 5
  • No model or system documentation was found for the Genetics Center's own models
  • The AI risk factors in Item 1A of the 10-K could not be read
Sources for Transparency (5)
  1. Regeneron Pharmaceuticals, Inc.: Position Statement on Responsible Use of Artificial Intelligence · 1 July 2025 · secondary source
  2. Regeneron Pharmaceuticals, Inc. (GlobeNewswire): Regeneron Collaborates with TriNetX to Access De-identified Electronic Health Records of 300 Million Patients · 2 April 2026 · secondary source
  3. Regeneron Pharmaceuticals, Inc.: Regeneron Genetics Center Data Privacy Statement · 1 May 2025 · secondary source
  4. Regeneron Pharmaceuticals, Inc.: From Human Data to Human Health (Regeneron Genetics Center) · 3 November 2026 · secondary source
  5. Fortune: Truveta Genome Project with Regeneron and Illumina · 16 January 2025 · secondary source

4 · Why the harm rule does not apply

The harm rule does not apply: within the window there is no judgment, authority decision or fine on harm from Regeneron's AI; the service provider incident is unrelated to AI.

5 · Controversies (1)

6 · What remains open

  • AI-related risk factors in the FY2025 10-K, whose Item 1A was truncated on retrieval
  • Design and status of the AI risk framework with risk taxonomy, approval process and AI inventory
  • Validation and monitoring of AI in GxP processes
  • Consent and governance in the use of TriNetX and Truveta data for AI training
  • Content of the 2024 and 2025 sustainability reports on AI, data protection and cybersecurity

7 · How it was assessed

Cut-off date: 3 November 2026 · 42 searches, 32 fetches.

Primary documents read (10)
  • Form 10-K FY2025 (Item 1 through Government Regulation; Item 1C via R29; Note 16 Legal Matters via R23)
  • Proxy Statement 2026 (HTML and courtesy PDF, each up to approximately 117,000 and 100,000 characters respectively)
  • Charter of the Digital Technology Committee
  • Position Statement on Responsible Use of Artificial Intelligence (July 2025)
  • Code of Business Conduct and Ethics (October 2026)
  • Achieving Our 2025 Responsibility Goals
  • RGC Data Privacy Statement (May 2025)
  • Form 8-K Voting Results 2024, 2025, 2026
  • Form 10-Q Q2 2026 (to Note 6)
  • Press releases: TriNetX (2026-04-02) and 23andMe (2025-05-19)

Research of 3 November 2026 under Globalance AI Footprint rulebook version 0

We assess documented practice in dealing with AI; this is not an investment recommendation. Three pillars, weights 40/40/20, harm rule.

Research of 3 November 2026 under Globalance AI Footprint rulebook version 0. Documented observations from public sources, no investment recommendation.

Important Notice. This material is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any financial instrument, nor does it constitute investment advice or a recommendation. The GI 100 Index is a rules-based strategy index of Globalance Bank. Investments involve risk, including the loss of capital invested. The final product documents (including FinSA) shall prevail in all cases.

Your company? Information on inclusion in the GI 100 Index →

What comes next